Evidence map›Paper›PMID 30543589›Full record

ReviewClinical advances in hematology & oncology : H&O2018

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.

Francesca Battaglin, Madiha Naseem, Heinz-Josef Lenz, Mohamed E Salem

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Clinical advances in hematology & oncology : H&O, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 5 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 5 syntheses or guidelines pooled it, 203 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Protein Expression Status ofLife (Basel, Switzerland) · 2026
    Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Francesca BattaglinUSC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California and Veneto Oncologic Institute IOV-IRCCS, Padua, Italy.
Madiha NaseemUSC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Heinz-Josef LenzUSC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Mohamed E SalemLevine Cancer Institute of the Carolinas HealthCare System, Charlotte, North Carolina.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Microsatellite instability (MSI) is a key biomarker in colorectal cancer (CRC), with crucial diagnostic, prognostic, and predictive implications. Testing for mismatch repair deficiency (MMR-D)/MSI is recommended during screening for Lynch syndrome, an autosomal-dominant hereditary disease that is characterized by germline mutations in the MMR genes and associated with an increased risk for several types of cancer. Additionally, MSI-high (MSI-H) status is associated with a better prognosis in early-stage CRC and a lack of benefit from adjuvant treatment with 5-fluorouracil in stage II disease. More recently, MSI has emerged as a predictor of sensitivity to immunotherapy-based treatments. The groundbreaking success of checkpoint inhibitors in MMR-D metastatic CRC has opened a new therapeutic scenario for patients with these tumors. MSI-H CRC, in both the sporadic and hereditary settings, is characterized by distinctive molecular and clinicopathologic features and represents a unique subset of CRC that is the object of growing interest and fervent research efforts. This article, an overview of the expanding role of MSI in CRC, covers its clinical significance, the available data on molecular profiling, novel perspectives on MSI testing, biomarkers in MSI-H CRC, immunotherapy resistance, and novel immunotherapy strategies.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairMicrosatellite InstabilityChemotherapy, AdjuvantFluorouracilHumansImmunotherapyNeoplasm MetastasisNeoplasm StagingFluorouracil

Identifiers

PMID30543589
PMCPMC7493692
OpenAlexW2990310466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.